ArticleScientific reports2025
PTPRC is an immunotherapeutic predictor and serum biomarker in lung adenocarcinoma correlated with immune cell infiltration.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative Multi-Omics Analysis Reveals Molecular Signatures of Recurrence in Paired Primary and Recurrent High-Grade Serous Ovarian Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, with the poor overall prognosis. PTPRC is an essential protein on the surface of cells of the immunological systems However, the role of PTPRC in LUAD has not been clarified. UALCAN, HPA and TCGA database were used to investigate PTPRC expression in LUAD. HPA and Kaplan-Meier plotter database were used to explore the survival curve evaluating the prognostic value of PTPRC for LUAD. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis of PTPRC co-expression genes downloaded from cBioPortal database. Tumor immune dysfunction and exclusion (TIDE) was used to predict the immunotherapy response in different PTPRC subgroups. TIMER was used to analyze the correlation of PTPRC and immune cell infiltration or immune checkpoint expression level in LUAD. Serum PTPRC were detected by enzyme linked immunosorbent assay. In present study, the expression of PTPRC in LUAD was lower than that in the normal control group by means of bioinformatics analysis of the TCGA and UALCAN public databases. Moreover, LUAD patients with downregulated PTPRC expression exhibited poor overall survival. Besides, PTPRC was significantly positively correlated with various immune cells in LUAD. TIDE scores were markedly elevated in the PTPRC low-expression subgroup in contrast to the PTPRC high-expression subgroup, And PTPRC was also markedly positively associated with biomarkers of these infiltrated immune cells. PTPRC expression was also positively correlated with PD-1, PD-L1 and CTLA-4 expression. The serum PTPRC levels in LUAD patients were significantly reduced compared to the normal health group. The ROC curve of PTPRC concentration in LUAD was plotted to obtain an AUC = 0.7887, the cutoff value was 31.55 pg/mL, and the sensitivity and specificity were 77.78 and 70.00%, respectively. In summary, our results indicate that down-regulation of PTPRC predicts poor prognosis and associated with immune infiltration in LUAD and PTPRC is an immunotherapeutic predictor and serum biomarker in LUAD correlated with immune cell infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.